AMGN Amgen
- 309.410
- -5.440-1.73%
Amgen News
Express News | Alvotech Shares up 2.1% as Co Enters Into Agreement With DR Reddy's to Commercialize Biosimilar to Amgen's Bone Disease Drugs Prolia and Xgeva
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $5,700 Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 1.07% on an annualized basis producing an average annual return of 9.12%. Currently, Amgen has a market capitalization of $168
Barclays Sticks to Its Hold Rating for Amgen (AMGN)
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Sunday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AZN) announced the results of the Phase 2a COURSE trial of Tezspire (tezepelumab-ekko) for severe chronic obstructive pulmonary disease (COP
AstraZeneca, Amgen Release Mid-stage Data on Tezspire for COPD
HSBC Adjusts Price Target on Amgen to $356 From $322
Amgen (AMGN) has an average outperform rating and a price target range of $170 to $380, according to analysts polled by Capital IQ. Price: 312.94, Change: +0.47, Percent Change: +0.15
Amgen and AstraZeneca's Lung Disease Drug Study Reports Mixed Results
Amgen (AMGN) and AstraZeneca said late Sunday that the Phase 2a trial of their experimental drug, Tezspire, to treat moderate to very severe chronic obstructive pulmonary disease (COPD) did not show a
Reported Sunday, AstraZeneca And Amgen's TEZSPIRE Shows Potential For Future Chronic Obstructive Pulmonary Diseasetreatment In New Data Presented At ATS 2024
Late-breaking results from the Phase IIa COURSE trial provide insight into TEZSPIRE's impact on COPD exacerbations in patients with a broad range of eosinophil levelsThe Phase IIa COURSE trial was a p
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE TO HELP PATIENTS LIVING WITH COPD
Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status.
Express News | Amgen: New Data Presented Show Potential of Tezspire to Help Patients Living With Copd
Express News | Amgen: Safety and Tolerability Profile for Tezepelumab Was Consistent With Its Approved Severe Asthma Indication
Express News | Amgen: Subgroup Analysis Also Showed Tezepelumab Resulted in Numerical Improvements in Lung Function Measured by Forced Expiratory Volume
Express News | Amgen: In Patients With Bec ≥300 Cells/ΜL, Tezepelumab Led to Numerical Reduction of 46% in Rate of Moderate/Severe Exacerbations
Express News | Amgen: Treatment With Tezspire Led to 17% Numerical Reduction in Annual Rate of Moderate/Severe Copd Exacerbations Vs Placebo at Week 52
Express News | Amgen: Results From Phase 2a Course Trial Show Tezspire’s Impact on Copd Exacerbations in Patients With Broad Range of Eosinophil Levels
Express News | Amgen: Actively Planning Phase 3 Clinical Program Evaluating Tezepelumab in Patients With Copd
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift could revolutionize the cannabis industry. B
Amgen Unusual Options Activity
Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:AMGN).And retail traders should know.We noticed this today when the trades showed up on publicly available options h
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients
Thursday, the FDA approved Amgen Inc's (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on o
Analysis
Price Target
No Data
